Serum levels of ANOS1 serve as a diagnostic biomarker of gastric cancer: a prospective multicenter observational study
Serum levels of ANOS1 serve as a diagnostic biomarker of gastric cancer: a prospective multicenter observational study
复制标题
DOI：
10.1007/s10120-019-00995-z
复制
发表时间：
2020-03-01
期刊：
影响因子：
7.4
通讯作者：
Kodera, Yasuhiro
中科院分区：
文献类型：
--
作者：
Kanda, Mitsuro;Suh, Yun-Suhk;Kodera, Yasuhiro
研究背景：开发高性能的血清生物标志物可能会改善胃癌患者的治疗效果。我们先前确定了候选血清标志物，anosmin 1（ANOS 1），二氢嘧啶酶样3（DPYSL 3）和黑色素瘤相关抗原D2（MAGE-D2），并通过回顾性分析评估其临床意义。在这里，我们进行了一项前瞻性的多中心观察性研究，旨在验证这些潜在的markers.Methods的诊断性能，我们分析了血清水平手术前和手术后的三个潜在的生物标志物在胃癌患者和健康志愿者。结果胃癌患者与健康对照组的ANOS 1、DPYSL 3和MAGED 2的曲线下面积（AUC）分别为0.7058、0.6188和0.5031。ANOS 1检测的敏感性和特异性分别为0.36和0.85。区分I期GC患者与健康对照的ANOS 1的AUC值为0.7131。与健康对照组相比，I期胃癌患者血清ANOS 1水平显著升高（中位数分别为1179 ng/ml和461 ng/ml，P < 0.0001），原发性胃癌病变切除后血清ANOS 1水平降低（P < 0.0001）。血清ANOS 1和DPYSL 3水平的组合增加了区分GC患者和健康对照的AUC值。血清ANOS 1水平与癌胚抗原、糖链抗原19-9或其他炎症标志物无显著相关性。结论血清ANOS 1水平可作为胃癌的诊断工具。
Background Development of high-performance serum biomarkers will likely improve treatment outcomes of patients with gastric cancer (GC). We previously identified the candidate serum markers, anosmin 1 (ANOS1), dihydropyrimidinase-like 3 (DPYSL3), and melanoma-associated antigen D2 (MAGE-D2) and evaluated their clinical significance through a singlecenter retrospective analysis. Here we conducted a prospective multicenter observational study aimed at validating the diagnostic performance of these potential markers.Methods We analyzed serum levels before and after surgery of the three potential biomarkers in patients with GC and healthy volunteers. Quantification of serum and GC tissue levels was performed using an ELISA.Results Area under the curve (AUC) values that discriminated patients with GC from healthy controls were 0.7058, 0.6188, and 0.5031 for ANOS1, DPYSL3, and MAGED2, respectively. The sensitivity and specificity of the ANOS1 assay were 0.36 and 0.85, respectively. The AUC value of ANOS1 that discriminated patients with stage I GC from healthy controls was 0.7131. Serum ANOS1 levels were significantly elevated in patients with stage I GC compared with those of healthy controls (median 1179 ng/ml and 461 ng/ml, respectively, P < 0.0001) and decreased after resection of primary GC lesions (P < 0.0001). The combination of serum ANOS1 and DPYSL3 levels increased the AUC value that discriminated patients with GC from healthy controls. Serum levels of ANOS1 did not significantly correlate with those of carcinoembryonic antigen, carbohydrate antigen 19-9, or other markers of inflammation.Conclusions Serum levels of ANOS1 may serve as a useful diagnostic tool for managing GC.